Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

A Systems Oncology Approach Identifies NT5E as a Key Metabolic Regulator in Tumor Cells and Modulator of Platinum Sensitivity.

Nevedomskaya E, Perryman R, Solanki S, Syed N, Mayboroda OA, Keun HC.

J Proteome Res. 2016 Jan 4;15(1):280-90. doi: 10.1021/acs.jproteome.5b00793. Epub 2015 Dec 17.

2.

Alternative splicing of human NT5E in cirrhosis and hepatocellular carcinoma produces a negative regulator of ecto-5'-nucleotidase (CD73).

Snider NT, Altshuler PJ, Wan S, Welling TH, Cavalcoli J, Omary MB.

Mol Biol Cell. 2014 Dec 15;25(25):4024-33. doi: 10.1091/mbc.E14-06-1167. Epub 2014 Oct 8.

3.

NT5E (CD73) is epigenetically regulated in malignant melanoma and associated with metastatic site specificity.

Wang H, Lee S, Nigro CL, Lattanzio L, Merlano M, Monteverde M, Matin R, Purdie K, Mladkova N, Bergamaschi D, Harwood C, Syed N, Szlosarek P, Briasoulis E, McHugh A, Thompson A, Evans A, Leigh I, Fleming C, Inman GJ, Hatzimichael E, Proby C, Crook T.

Br J Cancer. 2012 Apr 10;106(8):1446-52. doi: 10.1038/bjc.2012.95. Epub 2012 Mar 27.

4.

CD73 is associated with poor prognosis in high-grade serous ovarian cancer.

Turcotte M, Spring K, Pommey S, Chouinard G, Cousineau I, George J, Chen GM, Gendoo DM, Haibe-Kains B, Karn T, Rahimi K, Le Page C, Provencher D, Mes-Masson AM, Stagg J.

Cancer Res. 2015 Nov 1;75(21):4494-503. doi: 10.1158/0008-5472.CAN-14-3569. Epub 2015 Sep 11.

5.
6.

NT5E CpG island methylation is a favourable breast cancer biomarker.

Lo Nigro C, Monteverde M, Lee S, Lattanzio L, Vivenza D, Comino A, Syed N, McHugh A, Wang H, Proby C, Garrone O, Merlano M, Hatzimichael E, Briasoulis E, Gojis O, Palmieri C, Jordan L, Quinlan P, Thompson A, Crook T.

Br J Cancer. 2012 Jun 26;107(1):75-83. doi: 10.1038/bjc.2012.212. Epub 2012 May 31.

7.

Juxta-articular joint-capsule mineralization in CD73 deficient mice: similarities to patients with NT5E mutations.

Li Q, Price TP, Sundberg JP, Uitto J.

Cell Cycle. 2014;13(16):2609-15. doi: 10.4161/15384101.2014.943567.

8.

MiR-422a promotes loco-regional recurrence by targeting NT5E/CD73 in head and neck squamous cell carcinoma.

Bonnin N, Armandy E, Carras J, Ferrandon S, Battiston-Montagne P, Aubry M, Guihard S, Meyronet D, Foy JP, Saintigny P, Ledrappier S, Jung A, Rimokh R, Rodriguez-Lafrasse C, Poncet D.

Oncotarget. 2016 Jul 12;7(28):44023-44038. doi: 10.18632/oncotarget.9829.

9.

Effect of two non-synonymous ecto-5'-nucleotidase variants on the genetic architecture of inosine 5'-monophosphate (IMP) and its degradation products in Japanese Black beef.

Uemoto Y, Ohtake T, Sasago N, Takeda M, Abe T, Sakuma H, Kojima T, Sasaki S.

BMC Genomics. 2017 Nov 13;18(1):874. doi: 10.1186/s12864-017-4275-4.

10.

Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients.

Holloway RW, Mehta RS, Finkler NJ, Li KT, McLaren CE, Parker RJ, Fruehauf JP.

Gynecol Oncol. 2002 Oct;87(1):8-16.

PMID:
12468336
11.

CD73 promotes proliferation and migration of human cervical cancer cells independent of its enzyme activity.

Gao ZW, Wang HP, Lin F, Wang X, Long M, Zhang HZ, Dong K.

BMC Cancer. 2017 Feb 15;17(1):135. doi: 10.1186/s12885-017-3128-5.

12.

Acquisition of new tumor cell properties by MSC-derived exosomes.

Yang Y, Bucan V, Baehre H, von der Ohe J, Otte A, Hass R.

Int J Oncol. 2015 Jul;47(1):244-52. doi: 10.3892/ijo.2015.3001. Epub 2015 May 11.

PMID:
25963929
13.
14.

Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells.

Samimi G, Safaei R, Katano K, Holzer AK, Rochdi M, Tomioka M, Goodman M, Howell SB.

Clin Cancer Res. 2004 Jul 15;10(14):4661-9.

15.

Role of CD73 in Disease: Promising Prognostic Indicator and Therapeutic Target.

Yang J, Liao X, Yu J, Zhou P.

Curr Med Chem. 2018;25(19):2260-2271. doi: 10.2174/0929867325666180117101114. Review.

PMID:
29345574
16.

Chemotherapy induces enrichment of CD47+/CD73+/PDL1+ immune evasive triple-negative breast cancer cells.

Samanta D, Park Y, Ni X, Li H, Zahnow CA, Gabrielson E, Pan F, Semenza GL.

Proc Natl Acad Sci U S A. 2018 Feb 6;115(6):E1239-E1248. doi: 10.1073/pnas.1718197115. Epub 2018 Jan 24.

17.

Ankyrin repeat domain 1, ANKRD1, a novel determinant of cisplatin sensitivity expressed in ovarian cancer.

Scurr LL, Guminski AD, Chiew YE, Balleine RL, Sharma R, Lei Y, Pryor K, Wain GV, Brand A, Byth K, Kennedy C, Rizos H, Harnett PR, deFazio A.

Clin Cancer Res. 2008 Nov 1;14(21):6924-32. doi: 10.1158/1078-0432.CCR-07-5189.

18.

NT5E mutations that cause human disease are associated with intracellular mistrafficking of NT5E protein.

Fausther M, Lavoie EG, Goree JR, Baldini G, Dranoff JA.

PLoS One. 2014 Jun 2;9(6):e98568. doi: 10.1371/journal.pone.0098568. eCollection 2014. Erratum in: PLoS One. 2015;10(3):e0118252.

19.

Ecto-5'-nucleotidase: a candidate virulence factor in Streptococcus sanguinis experimental endocarditis.

Fan J, Zhang Y, Chuang-Smith ON, Frank KL, Guenther BD, Kern M, Schlievert PM, Herzberg MC.

PLoS One. 2012;7(6):e38059. doi: 10.1371/journal.pone.0038059. Epub 2012 Jun 7.

20.

Genetic variation that predicts platinum sensitivity reveals the role of miR-193b* in chemotherapeutic susceptibility.

Ziliak D, Gamazon ER, Lacroix B, Kyung Im H, Wen Y, Huang RS.

Mol Cancer Ther. 2012 Sep;11(9):2054-61. doi: 10.1158/1535-7163.MCT-12-0221. Epub 2012 Jun 29.

Supplemental Content

Support Center